Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

OGT Appoints Dr Bob Holland as CMO

Published: Monday, October 21, 2013
Last Updated: Monday, October 21, 2013
Bookmark and Share
Company strengthens focus on cancer biomarkers.

Oxford Gene Technology (OGT) has announced the appointment of Dr Bob Holland as Chief Medical Officer.

Dr Holland (57), is an expert in biomarker-driven drug development. He has an impressive clinical track record with over 25 years’ experience in the pharmaceutical industry, where he has contributed to the development of significant medicines in neuroscience and oncology.

His long-standing interest in biomarkers led to the creation of an entirely new division at AstraZeneca - Personalized Healthcare & Biomarkers - which is dedicated to the application of molecular biology and imaging techniques to improve the discovery and development of new drugs.

As VP and Head of this division, Dr Holland was instrumental in the generation of a pipeline in which 14 developmental drug programmes were matched with potential companion diagnostic tests.

Dr Holland will add considerably to OGT’s expertise in cancer profiling and biomarker development. He will lead in clinical matters across the range of OGT’s business, working with the R&D and commercial teams to design and implement clinical development programmes to expand OGT’s next generation sequencing and microarray cancer profiling solutions and advanced biomarker programmes in prostate and colorectal cancer.

Commenting on his appointment, Dr Holland said, “The development and commercialization of biomarkers to aid diagnosis and to personalize treatment, particularly in oncology, is something that I have had a continued and unwavering interest in for many years. OGT is at the forefront of this area of medicine and I look forward to joining the team to take the Company’s innovative genomic solutions through to the clinic.”

Dr Mike Evans, CEO, OGT said, “At OGT, we believe in finding the right people with the right expertise to spearhead our business. Bob is an expert in the clinical development of cancer biomarkers, which is a great fit with our strategic aims. His experience will help further OGT’s position in these areas. We are pleased to have Bob on board to help guide our expansion of the range of clinical genomic products and services across the diagnostic pathway.”

The appointment of Dr Holland is another key step in OGT’s commitment to tackle cancer through the development of innovative profiling and diagnosis tools. In May, OGT launched a 58-gene solid tumour profiling next-generation sequencing service to advance vital research into personalized cancer care for breast, prostate, ovarian, lung and colorectal cancer.

In March, the Company was granted a license by The Institute of Cancer Research to develop and commercialize a new panel of diagnostic and prognostic microRNA markers for prostate cancer, and in February it signed an agreement with the Cancer Cytogenomics Microarray Consortium (CCMC) to design a whole genome, cancer-specific microarray which was launched in August.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

OGT Initiates Clinical Trial of New Array-Based NIPT
Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.
Tuesday, November 04, 2014
OGT Supports Earlier Lupus Diagnosis
Superior sensitivity and specificity compared to current laboratory tests.
Friday, May 10, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT to Host Company Showcase at BioTrinity 2012
Seminar to discuss company’s biomarker accelerator strategy for optimizing drug and diagnostic development.
Monday, April 23, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
OGT to Exhibit and Present at Molecular Medicine Tri-Con 2012
The conference will include an OGT presentation entitled “Integrated Biomarker Discovery: Multi-Method Approach to Enable Early Biomarker Success”, taking place on Tuesday 21st February at 15.50 in the Moscone North Convention Centre.
Friday, February 10, 2012
OGT Founder Professor Sir Ed Southern Awarded the 2011 MRC Millennium Medal
Pioneer of DNA microarray technology recognised for outstanding impact in the field of genetic analysis.
Monday, January 30, 2012
OGT Releases New Whitepaper for Aiding Biomarker Discovery
The new document explores the need for biomarkers as indicators of disease, and discusses the vast potential of autoantibodies as markers of early disease development.
Tuesday, January 24, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT Featured in the Sunday Times Biotech Supplement
The article entitled ‘Better diagnosis, less cost’, describes how OGT’s recent innovations will help push healthcare costs down, while improving the accuracy of early disease diagnosis.
Monday, January 24, 2011
OGT Announces Major Role in Large Scale Diabetes Study
Genefficiency™ aCGH microarray service to process extensive sample set linking CNVs to disease susceptibility.
Thursday, December 02, 2010
OGT Receives ISO/IEC 27001:2005 Accreditation
Certification highlights commitment to information security and confidentiality.
Thursday, September 16, 2010
OGT Attracts Over 200 Delegates to its aCGH Satellite Meeting at ESHG 2010
Delegates heard presentations on how OGT’s array comparative genomic hybridization solutions can help advance disease and cytogenetics research.
Tuesday, July 13, 2010
OGT to Present at International Workshop on the Search for New IVD Biomarkers
Dr. John Anson, Vice President of Biomarker Discovery at OGT, will speak on ‘Screening for novel oncology biomarker panels using both DNA and protein microarrays’.
Wednesday, June 16, 2010
Scientific News
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
New Test Detects All Viruses
A new test detects virtually any virus that infects people and animals, according to research at Washington University School of Medicine in St. Louis, where the technology was developed.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Chip-Based Technology Enables Reliable Direct Detection of Ebola Virus
Hybrid device integrates a microfluidic chip for sample preparation and an optofluidic chip for optical detection of individual molecules of viral RNA.
Diagnostics Breakthrough Brings Viral Sequencing to Doctors’ Toolkit
New screening tool produces up to 10,000-fold improvement in viral matches compared with traditional high-throughput methods.
New Cell Type May Help Explain Dangerous Food Allergies
Researchers have discovered a new cell type that appears to drive life-threatening food allergies and may help explain why some people get severe allergic reactions and others do not.
Molecular Diagnostics At Home
Electrochemical test's sensing principle may be generalized to many different targets, leading to inexpensive devices that could detect dozens of disease markers in less than 5 minutes.
DNA Alterations as Among Earliest to Occur in Lung Cancer Development
Genetic footprints of precancer detectable in some blood samples.
New, Improved Approach To Mammograms
Detecting breast cancer in women with dense mammary tissues could become more reliable with a new mammogram procedure that researchers have now tested in pre-clinical studies of mice.
Undiagnosed Diseases Network Launches Online Application Portal
UDN Gateway enables patients to apply to national network of clinical sites.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos